A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival.
CD38
HPV test
LCK
cervical cancer
cervical intraepithelial neoplasia (CIN)
conization
gene expression analyses
immune activation
perforin
prognostic biomarker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Nov 2021
16 Nov 2021
Historique:
received:
23
09
2021
revised:
10
11
2021
accepted:
13
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The purpose of this study was to establish a gene signature that may predict CIN3 regression and that may aid in selecting patients who may safely refrain from conization. Oncomine mRNA data including 398 immune-related genes from 21 lesions with confirmed regression and 28 with persistent CIN3 were compared. L1000 mRNA data from a cervical cancer cohort was available for validation (
Identifiants
pubmed: 34830895
pii: cancers13225737
doi: 10.3390/cancers13225737
pmc: PMC8616457
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Folke Hermansen
ID : Year 2017-2019
Organisme : Western Norway Regional Health Authority
ID : 27804 and 911634
Organisme : University of Bergen
ID : Annual
Organisme : The Research Council of Norway
ID : 273280
Organisme : Norwegian Cancer Society
ID : 190202
Références
Br J Cancer. 1991 Sep;64(3):559-65
pubmed: 1911199
Int J Cancer. 2006 Mar 15;118(6):1481-95
pubmed: 16206285
Acta Obstet Gynecol Scand. 1998 May;77(5):558-63
pubmed: 9654180
Int J Oncol. 2020 Jul;57(1):338-354
pubmed: 32319590
Int J Cancer. 2013 Feb 15;132(4):854-67
pubmed: 22752992
Nat Commun. 2013;4:2612
pubmed: 24113773
Gynecol Oncol. 2012 Dec;127(3):489-94
pubmed: 23017821
Gynecol Obstet Invest. 2019;84(6):562-567
pubmed: 31055567
Front Oncol. 2019 Aug 02;9:682
pubmed: 31428574
Mol Carcinog. 2017 Oct;56(10):2245-2257
pubmed: 28544069
J Natl Cancer Inst. 2008 Apr 2;100(7):513-7
pubmed: 18364507
Lancet. 2007 Nov 10;370(9599):1609-21
pubmed: 17993361
Int J Gynecol Cancer. 2019 Jul;29(6):1003-1009
pubmed: 31079058
Int J Gynecol Pathol. 1993 Apr;12(2):186-92
pubmed: 8463044
Arch Pathol Lab Med. 2020 Jun;144(6):725-734
pubmed: 31718233
Hum Pathol. 2016 May;51:64-74
pubmed: 27067784
Lancet Oncol. 2008 May;9(5):425-34
pubmed: 18407790
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Gynecol Oncol. 1995 Oct;59(1):143-7
pubmed: 7557600
Clin Cancer Res. 2005 Jul 1;11(13):4717-23
pubmed: 16000566
Cancer Cytopathol. 2019 Sep;127(9):586-597
pubmed: 31412167
Exp Mol Pathol. 2013 Oct;95(2):166-73
pubmed: 23791892
BMJ. 2018 Feb 27;360:k499
pubmed: 29487049
Biochem Biophys Res Commun. 2010 Nov 26;402(4):631-6
pubmed: 20971076
Sex Transm Dis. 2015 Jan;42(1):20-6
pubmed: 25504296
Gynecol Oncol. 2021 Sep;162(3):569-574
pubmed: 34226019
Int J Cancer. 2019 Nov 15;145(10):2629-2638
pubmed: 30734284
Int J Gynaecol Obstet. 2016 Mar;132(3):266-71
pubmed: 26643302
BMJ. 2008 Sep 18;337:a1343
pubmed: 18801869
Sex Transm Infect. 2018 Nov;94(7):522-527
pubmed: 29523719
Am J Obstet Gynecol. 2017 Oct;217(4):432.e1-432.e17
pubmed: 28599900
Gynecol Oncol. 2021 Aug;162(2):299-307
pubmed: 34116834
Arch Sex Behav. 2010 Aug;39(4):907-14
pubmed: 19330437
Bioinformatics. 2001 Apr;17(4):369-70
pubmed: 11301307
Infect Agent Cancer. 2012 Nov 05;7(1):30
pubmed: 23126423
PLoS One. 2012;7(9):e45114
pubmed: 23028792
Cells. 2019 Dec 24;9(1):
pubmed: 31878283
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
pubmed: 16030305
BMJ. 2008 Sep 18;337:a1284
pubmed: 18801868
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Int J Cancer. 2019 Apr 15;144(8):1975-1982
pubmed: 30246864
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
J Natl Cancer Inst. 2000 May 3;92(9):690-8
pubmed: 10793105
Int J Cancer. 2006 Sep 1;119(5):1108-24
pubmed: 16570271
Clin Microbiol Infect. 2020 May;26(5):579-583
pubmed: 31539637
Nat Rev Immunol. 2015 Jun;15(6):388-400
pubmed: 25998963
Front Immunol. 2019 Sep 04;10:2093
pubmed: 31552039
Oncogene Res. 1987 Sep-Oct;1(4):357-74
pubmed: 2835736
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
J Natl Cancer Inst. 1999 Feb 3;91(3):252-8
pubmed: 10037103
Oncoimmunology. 2015 Feb 25;4(2):e981457
pubmed: 25949879
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Obstet Gynecol. 2012 Dec;120(6):1465-71
pubmed: 23168774
Nat Commun. 2020 Apr 24;11(1):1999
pubmed: 32332850
BJOG. 2020 May;127(6):729-736
pubmed: 31880054
J Biol Chem. 2006 Apr 21;281(16):11322-31
pubmed: 16474166
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502
pubmed: 22308364
Clin Cancer Res. 2001 Feb;7(2):285-9
pubmed: 11234881
Br J Cancer. 2010 Sep 7;103(6):899-909
pubmed: 20717116
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5958-62
pubmed: 8650201
Medicine (Baltimore). 2020 Nov 13;99(46):e23155
pubmed: 33181688
Nat Rev Drug Discov. 2019 May;18(5):379-401
pubmed: 30760888
Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60
pubmed: 15298958
Cancer Discov. 2021 Aug;11(8):1896-1912
pubmed: 33990345
Syst Rev. 2019 Jun 7;8(1):132
pubmed: 31174598
BMJ. 2016 Jul 28;354:i3633
pubmed: 27469988
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32847986
Br J Cancer. 2021 May;124(10):1690-1698
pubmed: 33723390
J Clin Pathol. 2011 Apr;64(4):303-7
pubmed: 21421698
Cancer Res. 2005 Apr 1;65(7):2921-9
pubmed: 15805295
Int J Mol Sci. 2019 Jul 16;20(14):
pubmed: 31315298
Obstet Gynecol. 2021 Jun 1;137(6):1043-1053
pubmed: 33957649
Int J Mol Sci. 2020 Oct 15;21(20):
pubmed: 33076281